Long-term assays for carcinogenicity. 1990

G Della Porta, and T A Dragani
Division of Experimental Oncology A, Istituto Nazionale Tumori, Milan, Italy.

During the past two decades, the rodent bioassay for detection of chemical carcinogens has reached a high standard of performance with both an increased number of animals and dose levels and a more detailed assessment of findings. However, the basic principles of testing and evaluation of results have remained essentially unchanged. Problems such as the length of the testing, use of maximum tolerated dose (MTD), selection of strains, variability of spontaneous tumors, discordant results between mouse and rat, and the classification of chemical carcinogens according to their mechanism of action have all remained unsolved. By contrast, the results of short-term tests and of other biological analyses do not always show a direct correlation with those of the long-term bioassays; this can be interpreted as an indication of different mechanisms of carcinogenicity. Currently available medium-term tests may detect carcinogenic activity of chemicals at particular organs in a period of time (weeks to months) relatively shorter than that of the 2-year carcinogenesis bioassay, and they may also provide additional information on mechanisms of carcinogenicity.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D015197 Carcinogenicity Tests Tests to experimentally measure the tumor-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumors or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumor developed. Though this test differs from the DNA-repair and bacterial microsome MUTAGENICITY TESTS, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values. Tumorigenicity Tests,Carcinogen Tests,Carcinogenesis Tests,Carcinogenic Activity Tests,Carcinogenic Potency Tests,Carcinogen Test,Carcinogenesis Test,Carcinogenic Activity Test,Carcinogenic Potency Test,Carcinogenicity Test,Potency Test, Carcinogenic,Potency Tests, Carcinogenic,Test, Carcinogen,Test, Carcinogenesis,Test, Carcinogenic Activity,Test, Carcinogenic Potency,Test, Carcinogenicity,Test, Tumorigenicity,Tests, Carcinogen,Tests, Carcinogenesis,Tests, Carcinogenic Activity,Tests, Carcinogenic Potency,Tests, Carcinogenicity,Tests, Tumorigenicity,Tumorigenicity Test
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates

Related Publications

G Della Porta, and T A Dragani
January 1986, IARC scientific publications,
G Della Porta, and T A Dragani
January 1980, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Supplement,
G Della Porta, and T A Dragani
January 1980, IARC scientific publications,
G Della Porta, and T A Dragani
February 1988, Fundamental and applied toxicology : official journal of the Society of Toxicology,
G Della Porta, and T A Dragani
April 1984, Transplantation proceedings,
G Della Porta, and T A Dragani
January 1986, IARC scientific publications,
G Della Porta, and T A Dragani
January 1986, IARC scientific publications,
G Della Porta, and T A Dragani
January 1986, IARC scientific publications,
G Della Porta, and T A Dragani
January 1986, IARC scientific publications,
G Della Porta, and T A Dragani
January 1986, IARC scientific publications,
Copied contents to your clipboard!